Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers

European Journal of Preventive Cardiology

Volumn 23, Issue 7, 2016, Pages 758-768

  Schievink, Bauke ^a   De Zeeuw, Dick ^a   Smink, Paul A ^a   Andress, Dennis ^b   Brennan, John J ^b   Coll, Blai ^b   Correa Rotter, Ricardo ^c   Hou, Fan Fan ^d   Kohan, Donald ^e   Kitzman, Dalane W ^f   Makino, Hirofumi ^g   Parving, Hans Henrik ^h   Perkovic, Vlado ⁱ   Remuzzi, Giuseppe ^j,n   Tobe, Sheldon ^k   Toto, Robert ^l   Hoekman, Jarno ^m   Lambers Heerspink, Hiddo J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ABBVIE INC   (United States)

^c National Institute for Medica Sciences and Nutrition Salvador Zubiran   (Mexico)

^d SOUTHERN MEDICAL UNIVERSITY   (China)

^e UNIVERSITY OF UTAH   (United States)

^f WAKE FOREST SCHOOL OF MEDICINE   (United States)

^g OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^h Rigshospitalet   (Denmark)

ⁱ UNIVERSITY OF SYDNEY   (Australia)

^j MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^k SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^l UNIVERSITY OF TEXAS AT DALLAS   (United States)

^m UTRECHT UNIVERSITY   (Netherlands)

ⁿ Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII   (Italy)

more..

Author keywords

albuminuria; atrasentan; cardiovascular disease; renal disease; Type 2 diabetes

Indexed keywords

ATRASENTAN; CREATININE; PLACEBO; BIOLOGICAL MARKER; ENDOTHELIN RECEPTOR ANTAGONIST; PYRROLIDINE DERIVATIVE;

ADULT; AGED; ALBUMINURIA; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DRUG EFFECT; END STAGE RENAL DISEASE; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; CLINICAL TRIAL; COMPLICATION; DOSE RESPONSE; DRUG EFFECTS; FOLLOW UP; GLOMERULUS FILTRATION RATE; KIDNEY; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL; RENAL INSUFFICIENCY, CHRONIC; TIME FACTOR; TREATMENT OUTCOME;

AGED; BIOMARKERS; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIN RECEPTOR ANTAGONISTS; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HEART FAILURE; HUMANS; KIDNEY; MALE; MIDDLE AGED; PYRROLIDINES; RENAL INSUFFICIENCY, CHRONIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 84962441155     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1177/2047487315598709     Document Type: Article

References (21)

1. Gregg EW, Li Y, Wang J, et al. Changes in diabetes-related complications in the United States, 1990-2010. N Engl J Med 2014; 370: 1514-1523.
2. Heerspink HJ, de Zeeuw D,. The kidney in type II diabetes therapy. Rev Diabet Stud 2011; 8: 392-402.
3. Kohan DE, Pollock DM,. Endothelin antagonists for diabetic and non-diabetic chronic kidney disease. Br J Clin Pharmacol 2013; 76: 573-579.
4. Kohan DE, Pritchett Y, Molitch M, et al. Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy. J Am Soc Nephrol 2011; 22: 763-772.
5. Kohan DE, Barton M,. Endothelin and endothelin antagonists in chronic kidney disease. Kidney Int 2014; 8: 896-904.
6. Chandrashekar K, Juncos LA,. Endothelin antagonists in diabetic nephropathy: Back to basics. J Am Soc Nephrol 2014; 25: 869-871.
7. Wenzel RR, Littke T, Kuranoff S, et al. for the SPP301 (Avosentan) Endothelin Antagonist Evaluation in Diabetic Nephropathy Study investigators. Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J Am Soc Nephrol 2009; 20: 655-664.
8. Weber MA, Black H, Bakris G, et al. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: A randomised, double-blind, placebo-controlled trial. Lancet 2009; 374: 1423-1431.
9. Dhaun N, Melville V, Blackwell S, et al. Endothelin-A receptor antagonism modifies cardiovascular risk factors in CKD. J Am Soc Nephrol 2013; 24: 31-36.
10. de Zeeuw D, Coll B, Andress D, et al. The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy. J Am Soc Nephrol 2014; 25: 1083-1093.
11. Mann JFE, Green D, Jamerson K, et al. for the ASCEND Study Group. Avosentan for overt diabetic nephropathy. J Am Soc Nephrol 2010; 21: 527-535.
12. Kalra PR, Moon JCC, Coats AJS,. Do results of the ENABLE (endothelin antagonist bosentan for lowering cardiac events in heart failure) study spell the end for non-selective endothelin antagonism in heart failure? Int J Cardiol 2002; 85: 195-197.
13. Smink P, Hoekman J, Grobbee D, et al. A prediction of the renal and cardiovascular efficacy of aliskiren in ALTITUDE using short-term changes in multiple risk markers. Eur J Prev Cardiol 2013; 21: 434-441.
14. Smink PA, Miao Y, Eijkemans MJC, et al. The importance of short-term off-target effects in estimating the long-term renal and cardiovascular protection of angiotensin receptor blockers. Clin Pharmacol Ther 2014; 95: 208-215.
15. Heerspink HJL, Grobbee DE, de Zeeuw D,. A novel approach for establishing cardiovascular drug efficacy. Nat Rev Drug Discov 2014; 13: 942-942.
16. Lambers Heerspink HJ, Gansevoort RT, Brenner BM, et al. Comparison of different measures of urinary protein excretion for prediction of renal events. Journal of the American Society of Nephrology 2010; 21 (8): 1355-1360.
17. Hoekman J, Lambers Heerspink HJ, Viberti G, et al. Predictors of congestive heart failure after treatment with an endothelin receptor antagonist. Clinical Journal of the American Society of Nephrology 2014; 9 (3): 490-498.
18. Heerspink HL, de Zeeuw D,. Pharmacology: Defining the optimal dose of a new drug: A crucial decision. Nat Rev Nephrol 2009; 5: 498-500.
19. Temple R,. Enrichment of clinical study populations. Clin Pharmacol Ther 2010; 88: 774-778.
20. Schievink B, de Zeeuw D, Parving H-H, et al. The renal protective effect of angiotensin receptor blockers depends on intra-individual response variation in multiple risk markers. Br J Clin Pharmacol. Epub ahead of print 14 April 2015. DOI: 10.1111/bcp.12655.
21. Moons K, Kengne A, Grobbee D, et al. Risk prediction models: II. External validation, model updating, and impact assessment. Heart 2012; 98: 691-698.